Compare Hershey Co (HSY) vs 10X Genomics Inc (TXG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Hershey Co vs 10X Genomics Inc — how do they compare? Hershey Co trades at $162.36 (market cap $32.66B), while 10X Genomics Inc trades at $81 (market cap $10.07B). The key difference: Hershey Co is far larger — about 3.2× 10X Genomics Inc's market cap, and Hershey Co pays a 3.57% dividend while 10X Genomics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Hershey Co for 135 Days and 10X Genomics Inc for 91 Days on average.
| HSY | TXG | |
|---|---|---|
Market Cap | $32.66B | $10.07B |
Volume | 1,578,237 | 5,657,286 |
Sector | Consumer Staples | Health |
52-Week High | $236.28 | $97.74 |
52-Week Low | $157.61 | $11.48 |
Typical Hold Time | 135 Days | 91 Days |
Enterprise Value | $37.79B | $9.59B |
Dividend Yield | 3.57% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Hershey (HSY) trades at $162.74, up 1.5% with bearish technical signals but strong fundamentals. The stock shows consistent earnings beats (3 of last 4 quarters) with Q3 2026 results pending. Revenue grew to $11.69B in 2025, though net margin compressed to 7.55% from 19.82% in 2024. Analyst consensus targets $204.62 (25.7% upside) with 65.7% hold ratings. Recent news highlights dividend resumption and international leadership changes.
HSY presents a mixed outlook: valuation appears reasonable (P/E 22.2) with strong brand positioning, but faces margin pressure from commodity costs. The technical bearish trend near key support at $161 suggests near-term caution. Long-term investors may find value given dividend growth resumption and consistent market share, though cocoa price volatility remains a key risk.
TXG trades at $80.65, up 5.98% on the day, showing strong recent momentum despite a bearish technical signal. The company reported revenue of $642.82M for 2025 with a gross margin of 70.03%, but remains unprofitable with a net loss of $43.54M. Recent news highlights the launch of the Atera spatial biology platform and a patent victory, signaling innovation and competitive strength. Analyst consensus is mixed with a $74.30 price target below the current price, indicating caution on valuation.
The outlook for TXG hinges on commercial execution of new products like Atera to drive revenue growth and a path to profitability. Investment opportunity lies in its leading technology platform and expanding market demand in genomics. Key risks include persistent losses, high valuation multiples, and competitive pressures in the life sciences tools sector. The stock's recent rally faces a test near technical resistance at $81.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Hershey Co
Hershey is a leading confectionery manufacturer in the U.S. (around a $25 billion market), controlling around 46% of the domestic chocolate space (per IRI). Beyond its namesake label, the firm's mix has expanded over the last 85 years and now consists of 100 brands, including Reese's, Kit Kat, Kisses, and Ice Breakers. Hershey's products are sold in about 80 countries, albeit with just a high-single-digit percentage of sales coming from markets outside the U.S., including Brazil, India, and Mexico. The firm has sought inorganic opportunities to extend its reach beyond its core confection business, adding Amplify Snack Brands and its Skinny Pop ready-to-eat popcorn to its mix and Pirate Brands (including the Pirate's Booty, Smart Puffs, and Original Tings brands) over the past few years.
Read more on HSY →About 10X Genomics Inc
10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The product portfolio of the company includes Chromium Controller, Reagent Kits, 10x Compatible Products, and Informatics Software among others. The majority of its revenue is generated from consumables.
Read more on TXG →
